Has Jane Bell-Pitts received payments from drug or device companies?

Yes. Drug and device makers reported $2,562 in general payments to Jane Bell-Pitts across 125 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jane Bell-Pitts did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jane Bell-Pitts come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jane Bell-Pitts

Primary Care · Slidell, LANPI 1881832715

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 26.2% of the total. Reporting peaked in 2021 at $2,102 and has fallen 94.4% since, to $118 in 2025.

$2,562in general payments, 2019–2025

Across 125 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$671
AbbVie$318
GSK$243
Amgen$183
Biohaven Pharmaceuticals, Inc.$152
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$135
plus $860 from 17 others

What the payments were for

Food & beverage$2,562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	19	$671
AbbVie	20	$318
GSK	20	$243
Amgen	10	$183
Biohaven Pharmaceuticals, Inc.	3	$152
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	9	$135
Merck	8	$122
Gilead	1	$115
Lilly USA, LLC	6	$98
Mannkind Corporation	1	$83
Sanofi-aventis U.S. LLC	5	$73
Ironwood Pharmaceuticals, Inc	4	$73
Boehringer Ingelheim	4	$63
Amarin Pharma, Inc.	3	$60
Pfizer	2	$32
Johnson & Johnson	2	$28
Takeda Pharmaceuticals U.S.A., Inc.	2	$25
Abbott	1	$18
Otsuka America Pharmaceutical, Inc.	1	$16
Eisai Inc.	1	$14
Astellas Pharma US Inc	1	$14
Lifescan, Inc.	1	$14
Esperion Therapeutics, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,562 in reported general payments places this provider in the 80th percentile of 106 primary care providers in Louisiana.

See all primary care providers in Louisiana →

Medicare billing

Part B allowed, 2024

$21,245

Medicare patients

140

Services billed

828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lagevrio (Eua)Molnupiravir	13	$5,908
Azelastine Hcl	173	$4,132
PaxlovidNirmatrelvir/Ritonavir	18	$1,429
Albuterol Sulfate HfaAlbuterol Sulfate	47	$1,128
Ibuprofen	133	$643
Cefdinir	27	$578
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	42	$455
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	30	$421
Mupirocin	51	$401
ValacyclovirValacyclovir Hcl	14	$399
Oseltamivir Phosphate	13	$365
Cephalexin	28	$338
Fluticasone Propionate	28	$320
Methylprednisolone	36	$273
MoxifloxacinMoxifloxacin Hcl	13	$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
MerckLagevrio (Eua)	$122	$5,90813 claims
PfizerPaxlovid	$32	$1,42918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 primary care providers in Louisiana.